Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HS-10518 in healthy Chinese premenopausal females
NCT06118827Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of merigolix in endometriosis (8 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence of Adverse Events at Day 16, Assessment of safety and tolerability of HS-10518 at Day 16 and 1 more. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
merigolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT06118827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118827.